Eli Lilly’s Next Billion-Dollar Weight-Loss Drug May Be Even Better

Eli Lilly has established a dominant position in the anti-obesity market, driven by the strong performance of its chronic weight management medicine, Zepbound. This therapy has surpassed its primary competitor, Wegovy, in sales, positioning the company as a leader in a rapidly expanding health sector.

The Shift to Triple-Hormone Therapy

The success of Zepbound is attributed to its design as a dual GLP-1/GIP agonist. While competitors like Wegovy mimic only the GLP-1 hormone to regulate blood sugar and satiety, Zepbound activates both GLP-1 and GIP receptors simultaneously.

Eli Lilly is now advancing this science with an investigational drug called retatrutide. This next-generation medicine mimics three gut hormones: GLP-1, GIP and glucagon, aiming for even greater efficacy than its predecessors.

Clinical Trial Breakthroughs

Recent phase 3 results for retatrutide demonstrate significant weight loss in overweight or obese patients with at least one weight-related comorbidity. Patients receiving the highest dose lost an average of 28.3% of their body weight over 80 weeks.

In comparison, the placebo group in the same study lost only 2.2%. These results suggest a level of weight loss that is rarely seen in other medications, including Novo Nordisk’s CagriSema.

45.3% of patients on the highest dose of retatrutide achieved weight loss exceeding 30%. This is a result typically associated with bariatric surgery rather than pharmaceutical intervention.

Addressing an Untapped Market

Despite the growth of GLP-1 therapies, the market remains significantly underpenetrated. As of last year, only 12% of U.S. Adults were on GLP-1s, and only 18% had ever taken this category of drugs.

Eli Lilly is expanding its reach through diversified offerings, such as Foundayo, an oral anti-obesity pill. Management reports that roughly 80% of Foundayo prescriptions are issued to patients who have never previously used GLP-1s.

Future Outlook and Strategy

The introduction of retatrutide is unlikely to cannibalize Zepbound sales. Instead, the company may target underserved segments of the market and patients with very high BMIs who require more aggressive weight loss interventions.

With several other pipeline candidates in the weight-loss space and other therapeutic areas, Eli Lilly is likely to maintain its lead in the industry. These developments suggest the company may continue to deliver strong financial results over the long term.

Frequently Asked Questions

What is the difference between Zepbound and retatrutide?
Zepbound is a dual GLP-1/GIP agonist, while retatrutide is a next-generation medicine that mimics three gut hormones: GLP-1, GIP, and glucagon.

How effective was retatrutide in phase 3 trials?
Patients on the highest dose lost an average of 28.3% of their body weight over 80 weeks, with 45.3% of those patients achieving weight loss greater than 30%.

Who is the target audience for Eli Lilly’s new weight-loss medications?
The company is likely to target underserved market segments, new patients who have never used GLP-1s, and individuals with very high BMIs who need aggressive weight loss.